Alosetron hydrochloride
Alosetron hydrochloride structure
|
Common Name | Alosetron hydrochloride | ||
|---|---|---|---|---|
| CAS Number | 122852-69-1 | Molecular Weight | 330.812 | |
| Density | 1.34g/cm3 | Boiling Point | 648.1ºC at 760 mmHg | |
| Molecular Formula | C17H19ClN4O | Melting Point | 288-291ºC | |
| MSDS | Chinese USA | Flash Point | 345.8ºC | |
| Symbol |
GHS06, GHS09 |
Signal Word | Danger | |
Use of Alosetron hydrochlorideAlosetron Hcl is a Serotonin 5HT3-receptor antagonist that is used in treatment of irritable bowel syndrome.IC50 Value: Target: 5-HT ReceptorAlosetron has an antagonist action on the 5-HT3 receptors of the enteric nervous system of the gastrointestinal tract. While being a 5-HT3 antagonist like ondansetron, it is not classified or approved as an antiemetic. Since stimulation of 5-HT3 receptors is positively correlated with gastrointestinal motility, alosetron's 5-HT3 antagonism slows the movement of fecal matter through the large intestine, increasing the extent to which water is absorbed, and decreasing the moisture and volume of the remaining waste products. From Wikipedia. |
| Name | alosetron hydrochloride |
|---|---|
| Synonym | More Synonyms |
| Description | Alosetron Hcl is a Serotonin 5HT3-receptor antagonist that is used in treatment of irritable bowel syndrome.IC50 Value: Target: 5-HT ReceptorAlosetron has an antagonist action on the 5-HT3 receptors of the enteric nervous system of the gastrointestinal tract. While being a 5-HT3 antagonist like ondansetron, it is not classified or approved as an antiemetic. Since stimulation of 5-HT3 receptors is positively correlated with gastrointestinal motility, alosetron's 5-HT3 antagonism slows the movement of fecal matter through the large intestine, increasing the extent to which water is absorbed, and decreasing the moisture and volume of the remaining waste products. From Wikipedia. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.34g/cm3 |
|---|---|
| Boiling Point | 648.1ºC at 760 mmHg |
| Melting Point | 288-291ºC |
| Molecular Formula | C17H19ClN4O |
| Molecular Weight | 330.812 |
| Flash Point | 345.8ºC |
| Exact Mass | 330.124725 |
| PSA | 53.92000 |
| LogP | 3.14820 |
| Vapour Pressure | 1.1E-16mmHg at 25°C |
| Storage condition | Refrigerator |
| Symbol |
GHS06, GHS09 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301-H319-H411 |
| Precautionary Statements | P273-P301 + P310-P305 + P351 + P338 |
| Hazard Codes | T,Xi |
| Risk Phrases | 25-36-52/53 |
| Safety Phrases | 26-45 |
| RIDADR | UN 2811 6.1 / PGIII |
| HS Code | 2933990090 |
| HS Code | 2933990090 |
|---|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage.
J. Chem. Inf. Model. 50(7) , 1304-18, (2010) Blockage of the human ether-a-go-go related gene (hERG) potassium ion channel is a major factor related to cardiotoxicity. Hence, drugs binding to this channel have become an important biological end ... |
|
|
Quantitative benefit-risk assessment using only qualitative information on utilities.
Med. Decis. Making 32(6) , E1-15, (2012) Utilities of pertinent clinical outcomes are crucial variables for assessing the benefits and risks of drugs, but numerical data on utilities may be unreliable or altogether missing. We propose a meth... |
|
|
Clinical trials in irritable bowel syndrome: a review.
Rev. Recent Clin. Trials 8(1) , 9-22, (2013) Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders and it is characterized by episodes of abdominal pain and altered bowel functions. The specific bowel disturbances o... |
| Alosetron hydrochloride |
| 5-méthyl-2-[(4-méthyl-1H-imidazol-5-yl)méthyl]-2,3,4,5-tétrahydro-1H-pyrido[4,3-b]indol-1-one chlorhydrate |
| gr 68755c |
| 1H-pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-, monohydrochloride |
| 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-, hydrochloride (1:1) |
| 1H-pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-, hydrochloride (1:1) |
| LOTRONEX |
| MFCD03453647 |
| Alosetron HCl |
| GR-68755C |
| 5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one hydrochloride |
| 5-Methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one hydrochloride (1:1) |
| 5-Methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-onhydrochlorid |
| Alosetron (Hydrochloride) |